Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System

Rave Harpaz, William DuMouchel, Paea LePendu, Anna Bauer‐Mehren, Patrick Ryan, Nigam H. Shah

Clinical Pharmacology & Therapeutics · 2013 · 314 citations · 29 references

DOIFull text

Open access

Concepts

TL;DR

Signal‑detection algorithms are vital tools in pharmacovigilance, yet their performance characteristics remain largely unknown. Using a publicly available OMOP gold standard and a systematic evaluation, the authors assess FDA AERS SDAs, provide performance guidelines for various operating scenarios, and propose a method to identify optimal signaling thresholds based on misclassification tolerances. SDAs achieve reasonable predictive accuracy, with two performance classes identified; approaches addressing confounding and masking improve safety surveillance, though event detectability varies, suggesting some events may be better monitored with other data sources. Published in Clinical Pharmacology & Therapeutics, 2013, doi:10.1038/clpt.2013.24.

Abstract

Signal-detection algorithms (SDAs) are recognized as vital tools in pharmacovigilance. However, their performance characteristics are generally unknown. By leveraging a unique gold standard recently made public by the Observational Medical Outcomes Partnership (OMOP) and by conducting a unique systematic evaluation, we provide new insights into the diagnostic potential and characteristics of SDAs that are routinely applied to the US Food and Drug Administration (FDA) Adverse Event Reporting System (AERS). We find that SDAs can attain reasonable predictive accuracy in signaling adverse events. Two performance classes emerge, indicating that the class of approaches that address confounding and masking effects benefits safety surveillance. Our study shows that not all events are equally detectable, suggesting that specific events might be monitored more effectively using other data sources. We provide performance guidelines for several operating scenarios to inform the trade-off between sensitivity and specificity for specific use cases. We also propose an approach and demonstrate its application in identifying optimal signaling thresholds, given specific misclassification tolerances. Clinical Pharmacology & Therapeutics (2013); 93 6, 539–546. doi:10.1038/clpt.2013.24

References

29